Atlas Trials

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Clinical trial NCT02052739 · COMPLETED

Trial details

NCT number
NCT02052739
Sponsor
Supernus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Super-refractory Status Epilepticus
Start date
2014-03-21
Primary completion
2015-05-03
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.